About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

NCT00989651

Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Study identifier: NCT00989651
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbott)

Eligibility:

  • Histologically confirmed newly diagnosed ovarian epithelial, fallopian tube, or primary peritoneal carcinoma, including one of the following histologic cell types:
  • Stage II-IV disease defined surgically with either optimal (≤ 1 cm) or suboptimal residual disease
  • Has undergone initial surgery for diagnosis, staging, and cytoreduction within the past 1-12 weeks
  • No current diagnosis of borderline ovarian epithelial tumor (formerly "tumors of low malignant potential") or recurrent invasive ovarian epithelial, primary peritoneal, or fallopian tube cancer treated with surgery only (e.g., stage IA or IB low-grade ovarian epithelial or fallopian tube cancers)
  • More than 5 years since prior chemotherapy for any abdominal or pelvic tumor
  • Prior adjuvant chemotherapy for localized breast cancer is allowed provided it was completed > 3 years ago AND the patient remains free of recurrent or metastatic disease
  • No prior radiotherapy to any portion of the abdominal cavity or pelvis

Type of study:

Phase I

Treatment:

  • Patients receive one of two regimens of bevacizumab, carboplatin, paclitaxel, and veliparib

Study site:

Missouri

Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
Saint Louis, Missouri, 63110
Contact: David G. Mutch, MD 314-362-3181  

New York
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065
Contact: Katherine M. Bell-McGuinn 212-639-8895

Ohio
Case Comprehensive Cancer Center
Cleveland, Ohio, 44106-5065
Contact: Clinical Trials Office - Case Comprehensive Cancer Center 800-641-2422

Oklahoma
Oklahoma University Cancer Institute
Oklahoma City, Oklahoma, 73104
Contact: Robert S. Mannel, MD 405-271-8787

Rhode Island
Women and Infants Hospital of Rhode Island
Providence, Rhode Island, 02905
Contact: Clinical Trials Office - Women and Infants Hospital of Rhode I 401-274-1122

Virginia
University of Virginia Cancer Center
Charlottesville, Virginia, 22908
Contact: Linda R. Duska, MD 434-924-5100

Wisconsin
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
Madison, Wisconsin, 53792-6164
Contact: Clinical Trials Office - University of Wisconsin Paul P. Carbo 608-262-5223

 

Page updated 08/31/11


Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org